WellDoc announced a pilot program with Providence Health & Services to examine the use of WellDoc’s BlueStar, an FDA-cleared, proven digital therapeutic for individuals with type 2 diabetes. Providence Health & Services has utilized the power and innovation of mobile technology into clinical practice before and is now carrying it into the diabetes management arena.
The pilot program will take place in the Providence Health & Services Oregon/SW Washington Region. It will include individuals living with type 2 diabetes and will evaluate the impact of a digital therapeutic—when used in conjunction with the support of a dedicated Diabetes Educator—on user engagement, retention, satisfaction and clinical outcomes.
BlueStar, powered by WellDoc, is an FDA-cleared, proven digital therapeutic that is an in-app coach engaging people with type 2 diabetes. It delivers personalized, real-time feedback, as well as diabetes educational tools that are actionable and individualized. Specifically, WellDoc has developed more than 30 peer-reviewed publications and presentations on BlueStar, including two randomized, controlled clinical trials.Clinical evidence shows a 1.7 to 2.0-point mean A1C reduction for adults living with type 2 diabetes who used BlueStar.
BlueStar harnesses evidence-based diabetes management, behavior management, and user experience to engage and provide individualized guidance when needed to people with type 2 diabetes. It provides this within a scalable self-management platform built on adaptive in-app coaching and actionable patient-generated health data. This platform is designed to connect adults living with type 2 diabetes, their health care team members, and payers through enhanced communication and support – resulting in proven clinical outcomes and cost savings.
“We’re pleased to announce this pilot program with Providence Health & Services,” said WellDoc President and CEO Kevin McRaith. “We expect great outcomes from this initial engagement and look forward to expanding our partnership to scale to meet the needs of all Providence patients living with type 2 diabetes.”
